Corporate Tax Inversions Unlikely To Lower Medical Product Prices, Senate Panel Told
This article was originally published in The Pink Sheet Daily
Executive Summary
Finance Committee Chairman Wyden questions the suggestion that corporate tax inversions by pharmaceutical manufacturers could lead to lower healthcare costs in the U.S.